A phase 3 trial of fasedienol, a first-in-class pherine nasal spray for social anxiety disorder (SAD), failed to beat placebo in the overall study population. But a post-hoc analysis found a meaningful benefit in patients with very severe SAD. Drugmaker Vistagen plans to discuss a regulatory pathway with the FDA, leaning on prior positive trial data and a future multi-dose study.
A phase 3 trial of fasedienol — a novel intranasal pherine designed to calm the brain's fear and anxiety circuits via the olfactory-limbic pathway — came up short in its primary endpoint. The PALISADE-4 trial enrolled 238 adults with social anxiety disorder (SAD) who received fasedienol or placebo 20 minutes before a public speaking challenge. The drug did not significantly reduce anxiety scores compared to placebo in the overall population.
However, a post-hoc analysis zeroing in on patients with very severe SAD (n=123) showed fasedienol produced a notably larger reduction in anxiety than placebo — a signal that has Vistagen cautiously optimistic. The company now plans to engage the FDA about a regulatory pathway, anchored by positive results from the earlier PALISADE-2 trial and a planned multi-dose study using a broader anxiety scale as the primary endpoint.
By the Numbers
Why it matters: Social anxiety disorder affects millions, and current treatment options are limited. While fasedienol didn't clear the bar for the full trial population, the strong signal in the most severely affected patients suggests there may still be a viable path forward — particularly for those who need it most.
